Stock Detail
MYRIAD GENETICS INC
Sector: Biotechnology
Latest Quote @ Thu Jun 6 08:22:34 (15 min delayed)
| $25.19 |
$26.35 |
$25.88 |
-0.56 |
-2.12% |
2.81M |
Last Day's Data
| $25.88 |
$27.11 |
$0.00 |
0.00% |
0.00 |
$26.44 |
| $26.32 |
$25.79 |
2.00 |
2.07B |
1.69M |
16.49 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 27.58 |
26.73 |
26.26 |
25.41 |
24.94 |
Stock Profile
Myriad Genetics, Inc., a biopharmaceutical company, engages in the development and marketing of therapeutic and molecular diagnostic products. Its lead drug candidate is Flurizan, a therapeutic drug for the treatment of Alzheimer's disease, which completed a Phase II human clinical trial in patients with mild to moderate Alzheimer's disease. Flurizan is also in a Phase IIb human clinical trial for the treatment of patients with premetastatic prostate cancer. The company's other products under development include MPC-6827, a small-molecule drug candidate that inhibits tubulin, an important protein involved in cell division for treatment of advanced solid tumors or metastatic brain tumors; MPC-2130, a novel apoptosis inducing small molecule for the treatment of metastatic tumors or blood cancers, as well as refractory cancer, ovarian cancer, and prostate cancer; and MPI-49839, a viral budding inhibitor for the treatment of AIDS. It also offers various predictive medicine products, including BRACAnalysis, which assesses a woman's risk of developing breast and ovarian cancer; COLARIS and COLARIS AP, which determine a person's risk of developing colon cancer; and MELARIS, which assesses a person's risk of developing malignant melanoma. Myriad Genetics has strategic alliances with Abbott Laboratories and E.I. du Pont de Nemours and Company. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
